Skip to main content
. 2023 Sep 25;23:1027. doi: 10.1186/s12913-023-10015-7

Table 2.

Socio-demographic, anthropometric, TB- and DM-related characteristics of study participants by glycaemic control outcome

All (N = 31) Controlleda (N = 12) Uncontrolleda (N = 14) Indeterminate (N = 5)
Age, years
 Mean, SD 52.0 (12.4) 48.2 (11.3) 60.6 (15.1) 52.0 (12.4)
 Median, Range 52.0 (30.0—83.0) 54.5 (30.0—69.0) 47.0 (31.0—66.0) 63.0 (43.0—83.0)
Sex
 Female 9 2 (22%) 5 (56%) 2 (22%)
 Male 22 10 (45%) 9 (41%) 3 (14%)
Region
 Negros Occidental 13 6 (46%) 6 (46%) 1 (8%)
 Cebu 10 5 (50%) 4 (40%) 1 (10%)
 Manila 8 1 (12%) 4 (50%) 3 (38%)
Income level
 Less than 5,000 PHP 13 6 (46%) 6 (46%) 1 (8%)
 5000—9999 PHP 5 1 (20%) 3 (60%) 1 (20%)
 > 10,000 PHP 13 5 (38%) 5 (38%) 3 (23%)
Marital status
 Single 4 1 (25%) 2 (50%) 1 (25%)
 Married 21 8 (38%) 11 (52%) 2 (10%)
 Divorced/separated 2 0 1 (50%) 1 (50%)
 Widowed 4 3 (75%) 0 1 (25%)
Unemployed
 Yes 18 7 (39%) 9 (50%) 2 (11%)
 No 13 5 (38%) 5 (38%) 3 (23%)
Insurance (public or private)
 No insurance 6 3 (50%) 2 (33%) 1 (17%)
 Insurance 21 7 (33%) 10 (48%) 4 (19%)
BMI classificationb
 Normal (18.5–25.0 kg/m2) 22 10 (45%) 10 (45%) 2 (9%)
 Underweight (< 18.5 kg/m2) 5 2 (40%) 2 (40%) 1 (20%)
 Overweight or obese (≥ 25.0 kg/m2) 4 0 2 (50%) 2 (50%)
Blood pressure at baselinec
 Normal (SBP < 120 mmHg, DBP < 80 mmHg) 10 5 (50%) 5 (50%) 0
 Elevated (SBP 120–129 mmHg, DBP < 80 mmHg) 2 2 (67%) 1 (33%) 0
 Stage 1 Hypertension (SBP 130–139 mmHg, DBP 80–89 mmHg) 11 3 (30%) 6 (60%) 1 (10%)
 Stage 2 Hypertension (SBP ≥ 140 mmHg, DBP ≥ 90 mmHg) 8 2 (25%) 2 (25%) 4 (50%)
Central obesityd
 Normal 4 3 (75%) 1 (25%) 0
 Central obesity 27 9 (33%) 13 (48%) 5 (19%)
Timing of DM diagnosise
 Newly diagnosed 13 6 (46%) 4 (31%) 3 (23%)
 Previously diagnosed 18 6 (33%) 10 (56%) 2 (11%)
Use of insulinf
 No use 26 9 (35%) 12 (46%) 5 (19%)
 Use 5 3 (60%) 2 (40%) 0
Use of metforminf
 No use 3 1 (33%) 1 (33%) 1 (33%)
 Use 28 11 (39%) 13 (46%) 4 (14%)
Report of any DM complicationg
 No 21 7 (33%) 9 (43%) 5 (24%)
 Yes 10 5 (50%) 5 (50%) 0
New versus relapse TB case
 New 20 6 (30%) 11 (55%) 3 (15%)
 Relapse 10 6 (60%) 2 (20%) 2 (20%)
Type of TB infection
 Drug Sensitive 20 6 (30%) 10 (50%) 4 (20%)
 Drug Resistant 11 6 (55%) 4 (36%) 1 (9%)

In addition to basic sociodemographic variables, characteristics shown only for factors found to be significant in univariable regressions with a Wald P-value < 0.1 (Table 1)

BMI Body Mass Index, DBP Diastolic Blood Pressure, DSSM Direct sputum smear microscopy, HbA1c Glycosylated haemoglobin, HT Hypertension, mmHg Millimetre of Mercury, PHP Philippine peso, SD Standard deviation, SBP Systolic blood pressure, TB Tuberculosis

aAmongst those with ≥ 2 HbA1c results: Uncontrolled (at least two study-measured HbA1c results equal to or greater than 8%); controlled (at least two study-measured HbA1c results less than 8%). Status was indeterminate if HbA1c data did not qualify into a glycaemic control category

bWorld Health Organization (WHO) criteria for adults [42]

c2017 American College of Cardiology and American Heart Association guidelines [43]

dWaist-to-hip ratio using WHO recommendations for diagnosing metabolic syndrome [44]; > 0.85 for women and > 0.9 for men

ePreviously-diagnosed: self-report of doctor diagnosis at enrolment into TB treatment, confirmed by self-reported use of standard glucose-lowering medication (insulin, gliclazide, metformin) if HbA1c result < 6.5%. Newly-diagnosed: HbA1c ≥ 6.5% test result during their TB treatment period, confirmed by self-report of an outside DM diagnosis or use of a standard glucose-lowering if no subsequent HbA1c results ≥ 6.5%

fSelf-reported any point during TB treatment

gAfter enrolment in TB treatment, report of experiencing diabetic complications [45]: ever lost a limb or digit not through trauma, ever had a bypass or stenting surgery in limbs, non-healing wound for three or more months, heart attack, stroke, bypass or stenting heart surgery, diagnosis of angina or heart failure, cataract or laser eye surgery, glaucoma, acquired blindness not due to trauma, difficulty seeing or disturbed vision, renal failure, and if participant had any symptom of distal symmetrical peripheral neuropathy using the Michigan Neuropathy Screening Instrument [46]